My wife, now deceased from MBC, took two ADCs that had the same payload (chemo) but two different antibody signatures. The first one did great for about 3 months. The second one failed, major progression. But the conclusion was still unknown, what information did that give us? Was it the cancer rejecting the antibody or mutating to overcome the chemo effects?
Tools we need (large scale):
- how can we identify when the cancer mutates, what part of the ADC is it rejecting? This information is valuable.
- how do we assign different payloads? Can this be scaled? Do new payload/antibody delivery systems need to go through the FDA each time? How do we streamline this to add a wider net to catch cancer mutations?
Tools we need (large scale):
- how can we identify when the cancer mutates, what part of the ADC is it rejecting? This information is valuable.
- how do we assign different payloads? Can this be scaled? Do new payload/antibody delivery systems need to go through the FDA each time? How do we streamline this to add a wider net to catch cancer mutations?